Quick Answer
Kura Oncology, Inc. reported Diluted EPS of $3.18 per share (loss) for fiscal year 2025.
Kura Oncology, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.18 | -57.4% |
| 2024 | -$2.02 | +2.9% |
| 2023 | -$2.08 | -2.5% |
| 2022 | -$2.03 | -3.0% |
| 2021 | -$1.97 | -16.6% |
| 2020 | -$1.69 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.85 | -34.9% | -13.3% |
| June 30, 2025 | -$0.75 | -27.1% | -13.6% |
| March 31, 2025 | -$0.66 | -11.9% | -4.8% |
| September 30, 2024 | -$0.63 | -26.0% | -6.8% |
| June 30, 2024 | -$0.59 | -11.3% | +0.0% |
| March 31, 2024 | -$0.59 | -18.0% | -18.0% |
| September 30, 2023 | -$0.50 | +5.7% | +5.7% |
| June 30, 2023 | -$0.53 | -1.9% | -6.0% |
- Kura Oncology, Inc. showed a decrease of -57.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Kura Oncology, Inc.’s diluted eps has declined by 88.2% (from $1.69 per share (loss) to $3.18 per share (loss)).
- The most recent figure is from Kura Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: